

1 **Title:** Association of Nirmatrelvir/Ritonavir treatment and COVID-19 neutralizing antibody titers
2 in a longitudinal healthcare worker cohort

3

4 Slade Decker, BS²

5 Shaoming Xiao, MSPH²

6 Carly Dillen, PhD³

7 Christina M. Schumacher, PhD, MHS²

8 Aaron M. Milstone, MD, MHS^{1,2}

9 Matthew Frieman, PhD³

10 Amanda K. Debes, PhD, MS¹

11 ¹ Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA

12 ² Johns Hopkins University School of Medicine, Baltimore, MD, USA

13 ³ Center for Pathogen Research, Department of Microbiology and Immunology, University of
14 Maryland School of Medicine, Baltimore MD 21212

15

16 **Correspondence:**

17 Amanda K. Debes PhD, MS

18 Department of International Health

19 615 N. Wolfe Street, E5036

20 Baltimore, MD 21205

21 adebes1@jhu.edu

22

23 **Manuscript Word Count:** 1386

24

25

26

27 **Abstract**

28 Nirmatrelvir/Ritonavir (NMV/r) is used for the treatment of COVID-19 infection. However,
29 rebound COVID-19 infections can occur after taking NMV/r. We examined neutralizing
30 antibodies to the SARS-CoV-2 spike protein before and after infection in people who did and did
31 not take NMV/r to determine if NMV/r impedes the humoral immune response.

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53 **Introduction**

54 In 2021, the United States Food and Drug Administration granted Emergency Use
55 Authorization to Nirmatrelvir/Ritonavir (NMV/r) for the treatment of mild-to-moderate COVID-19
56 infection. Soon after, the United States began providing anti-viral medication at no cost to
57 patients to reduce COVID-19 related hospitalizations and mortality. Reports then emerged of
58 rebound COVID-19 infections, defined as detectable viremia and/or symptoms, two to eight
59 days after completing NMV/r treatment [1-3]. One hypothesis to explain post-treatment rebound
60 infection is that early viral suppression reduces the immune response, including antibody
61 production, thereby predisposing to recurrent viremia and symptoms [4-6]. Prior studies have
62 found that for other viruses, in addition to SARS-CoV-2, early viral suppression can weaken
63 immune response to infection [4-5]. Our objective was to examine neutralizing antibodies to the
64 SARS-CoV-2 spike protein before and after infection in people who did and did not complete an
65 NMV/r treatment course to elucidate whether NMV/r impedes humoral immune response to
66 SARS-CoV-2.

67 **Methods**

68 *Study Population*

69 Healthcare workers (HW) were consented into an ongoing seroprevalence cohort beginning in
70 June 2020. Approximately every two to six months, HW provided serum samples and completed
71 surveys that captured data including COVID-19 infection dates and NMV/r use. We measured
72 changes in neutralization antibody levels using pre-/post-infection serum samples from each
73 individual meeting inclusion criteria and compared changes in neutralization antibody levels by
74 NMV/r use. HW who received NMV/r (treated) were matched to a HW who did not (untreated).
75 Inclusion criteria included: 1) COVID-19 infection (positive PCR or antigen test); 2) no prior
76 infection or receipt of vaccine dose within 90 days of pre-infection serum collection; 3) had
77 serum collected and stored within 90 days before infection, 4) had serum collected and stored at

78 least 10 days post-infection. Treated HW were matched to untreated HW who had: 1) an
79 infection date +/- 14 days of a treated HW; and 2) dates of both the pre- and post-infection
80 serum collection were +/- 7 days of the treated HW serum collection. This study was approved
81 by the Johns Hopkins University institutional review board.

82 *Neutralization assay*

83 Neutralizing antibody titers to the spike protein of SARS-CoV-2 (WA-1) for pre- NMV/r and post-
84 NMV/r (treated) samples were compared with untreated controls to determine if NMV/r had a
85 measurable response on neutralizing antibody response to infection. For the neutralization titer
86 assays (NT), serum samples were heat inactivated at 56°C for 30 min to remove complement
87 and allowed to equilibrate to room temperature prior to processing for neutralization titer.

88 Samples were diluted in duplicate to an initial dilution of 1:10 followed by 1:2 serial dilutions
89 resulting in a 12-dilution series with each well containing 100µL. All dilutions were performed in
90 DMEM (Quality Biological), supplemented with 10% (v/v) fetal bovine serum (heat inactivated,
91 Sigma), 1% (v/v) penicillin/streptomycin (Gemini Bio-products) and 1% (v/v) L-glutamine (2 mM
92 final concentration, Gibco). Dilution plates were then transported into the BSL-3 laboratory and
93 SARS-CoV-2-GFP inoculum was added to each well to result in a multiplicity of infection (MOI)
94 of 0.01 upon transfer to titering plates. A non-treated, virus-only control and a mock infection
95 control were included on every plate. The sample/virus mixture was then incubated at 37°C
96 (5.0% CO₂) for 1 hour before transferring to 96-well flat bottom plates with confluent Vero-
97 TMPRSS2 cells. Titer plates were incubated at 37°C (5.0% CO₂) for 24 hours after cells were
98 fixed with 10% neutral buffered formalin (Sigma) for at least 1 hour at 4°C as per BSL3 SOP.
99 Plates were removed from the BSL3 and stained with Hoechst 33342 (Thermo Scientific)
100 diluted 1:2000 in PBS for 10 minutes. Cells were washed with PBS and imaged with a Celigo
101 high content imager (Nexcelom).

102 *Statistical analyses*

103 The ratio of the half maximal inhibitory concentration (IC₅₀) between matched participants pre-
104 and post-infection were compared using Wilcoxon signed rank test. Statistical significance was
105 defined as $p < 0.05$. Analyses were performed in R, version 4.2.2 (R Foundation for Statistical
106 Computing, Vienna, Austria).

107 **Results**

108 Of 1353 HW who reported COVID-19 infection, 65 reported NMV/r use, and 32 met
109 inclusion criteria from which 21 could be matched to a control. We performed neutralization
110 assays on serum from 21 HW treated and 21 untreated with NMV/r. Of the 42 participants, the
111 majority were female (86%) and White (90%). Treated participants were older (median: 50.9;
112 IQR: 44.6-62.0 years) and less frequently female (78% vs. 94%) than untreated participants
113 (median: 35.5; IQR: 32.6-40.9). Treated and untreated participants did not substantially differ by
114 pre-existing conditions or prior exposure to SARS-CoV-2 spike protein.

115 The pre-infection and post-infection half maximal inhibitory concentrations (IC₅₀) in the
116 treated group were lower than in the untreated group (Figure 1A). The median (IQR) NT of the
117 treated group pre- and post-infection was 980.0 (477.3-2720.3) and 4394.0 (1986.4-7608.4),
118 respectively (Supplemental Table). The median (IQR) NT of the untreated group pre- and post-
119 infection was 1247.5 (433.0, 2032.7) and 7316.0 (4335.0, 10834.0) respectively (Supplemental
120 Table). Of the treated and untreated groups, 67% and 61%, respectively, had an NT greater
121 than or equal to 800 pre-infection, and 100% of both groups had an NT greater than or equal to
122 800 post-infection. The ratio of IC₅₀ between the treated and untreated groups pre- and post-
123 infection were similar (median: 0.64 and 0.76, respectively, $p = 0.7$) (Figure 1B).

124 **Discussion**

125 This study demonstrates that taking NMV/r after COVID-19 infection does not impact the
126 host humoral immune response. Our results show that the range between pre-infection and
127 post-infection neutralizing antibody titers for the treated and untreated groups was nearly
128 identical, with median ratios in IC₅₀ values of 0.64 and 0.76, respectively. While this study

129 demonstrates that there is no significant difference in post-infection NT between treated and
130 untreated groups, it highlights that despite high pre-infection NTs, both groups were still
131 infected. Other researchers have attempted to create clarity on the NT threshold of protection,
132 but it remains poorly defined [7].

133 Our goal was to see if NMV/r has an impact on host humoral immune response during
134 COVID-19 infection and we assessed this by comparing increase of neutralizing antibodies pre-
135 to post-infection. A recent publication accessing immunoglobulin G (IgG) and Omicron-specific
136 neutralizing antibodies in individuals taking NMV/r using only post-infection data reported similar
137 findings, including similar neutralizing antibody levels when taking the medication and when not,
138 with an overall conclusion that NMV/r treatment does not impact adaptive immune response [8].
139 Our results suggest that concern about early viral suppression reducing immune response to
140 infection should not be a barrier or deterrent to taking NMV/r.

141 We believe the observed difference in age may be due to indication bias for treatment
142 based on age; older age has been associated with higher risk for severe COVID-19 infection,
143 leading to an increase in older individuals taking NMV/r. The difference in pre-infection and
144 post-infection NT between the treated and untreated groups may be attributed to the age
145 differences across study groups. Prior work has found that compared to older people, younger
146 people produce a higher antibody response to COVID-19 [9-10].

147 Limitations of this study include a small sample size ($n = 42$), and a demographically
148 homogenous cohort of HW that limits generalizability, although our sample size is significantly
149 larger than those used in a similar prior study [8]. Secondly, we only performed NT on WA-1
150 SARS-CoV-2. Despite the antigenic differences between original SARS-CoV-2 and its
151 numerous variants, including Omicron, we tested only WT WA1 strain as that is an identical
152 match to the vaccine strain. Our study population consisted entirely of vaccinated individuals, so
153 using the same strain as the vaccine would result in the most robust responses.

154 The results of this study show that NMV/r medication does not have a significant impact
155 on humoral immune response post-infection. This finding should reassure those infected with
156 COVID-19 that they can take NMV/r without negatively impacting their humoral immune
157 response. More work is needed to break down barriers that have prevented the acceptance of
158 this drug as an important treatment option for COVID-19. This study examined immune
159 response relatively soon after infection; future research is needed to examine the impact of
160 rebound COVID-19 infections on neutralizing antibody titers, and the rate of anti-SARS-CoV-2
161 antibody degradation in individuals who take NMV/r compared to those who do not over longer
162 time periods post-infection. Our findings demonstrate that those at high-risk can take NMV/r to
163 reduce the severity and length of mild to moderate COVID-19 infection without detriment to their
164 post-infection humoral immune response.

165
166 **Acknowledgements:** The authors would like to thank Annie Kuh, LuAnn Rezavi, and other
167 members of the Johns Hopkins Hospital Clinical Immunology Laboratory, Danielle Koontz,
168 Anushree Aneja and Emily Egbert of the Johns Hopkins Division of Pediatric Infectious
169 Diseases, and Matt Courtemanche from the Johns Hopkins University School of Medicine. We
170 would also like to thank Dr. Ralph Baric (UNC Chapel Hill) for providing the SARS-CoV-2-GFP
171 inoculum. Research reported in this publication was supported in part by the National Institute of
172 Allergy and Infectious Diseases of the National Institutes of Health (NIH) under award number
173 K24AI141580 (A.M.), HHSN272201400008C / 0258-0686-4609 (MF and CD), and the
174 generosity of the collective community of donors to the Johns Hopkins University School of
175 Medicine and the Johns Hopkins Health System for Covid-19 research.

176
177 **Conflict of Interest Disclosure:** All authors report no conflicts.


178
179 **References**

- 180 1. Wang L, Berger NA, Davis PB, Kaelber DC, Volkow ND, Xu R. Covid-19 rebound after
181 Paxlovid and molnupiravir during January-June 2022. medRxiv [Preprint]. June 22, 2022
182 [cited 2023 March 09]. Available from: <https://doi.org/10.1101/2022.06.21.22276724>.
- 183 2. Wang L, Volkow ND, Davis PB, Berger NA, Kaelber DC, Xu R. Covid-19 rebound after
184 Paxlovid treatment during Omicron Ba.5 vs ba.2.12.1 subvariant predominance period.
185 medRxiv [Preprint]. August 06, 2022 [cited 2023 Mar 9]. Available from:
186 <https://doi.org/10.1101/2022.08.04.22278450>.
- 187 3. Boucau J, Uddin R, Marino C, et al. Characterization of Virologic rebound following
188 Nirmatrelvir-Ritonavir treatment for coronavirus disease 2019 (covid-19). Clin Infect Dis,
189 **2022**; 76: 526–529.
- 190 4. Charness ME, Gupta K, Stack G, et al. Rebound of SARS-CoV-2 Infection after
191 Nirmatrelvir–Ritonavir Treatment. N Engl J Med, **2022**; 387:1045-1047.
- 192 5. Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory virus
193 infection: balancing virus clearance and immunopathology. Semin Immunopathol, **2016**;
194 38: 71-82.
- 195 6. Rubin R. From positive to negative to positive again-the mystery of why COVID-19
196 rebounds in some patients who take Paxlovid. JAMA, **2022**; 327: 2380-2382.
- 197 7. Khoury DS, Schlub TE, Cromer D, et al. Correlates of Protection, Thresholds of
198 Protection, and Immunobridging among Persons with SARS-CoV-2 Infection. Emerg
199 Infect Dis, **2023**; 29: 381-388.
- 200 8. Epling BP, Rocco JM, Boswell KL, et al. Clinical, Virologic, and Immunologic evaluation
201 of symptomatic coronavirus disease 2019 rebound following Nirmatrelvir/Ritonavir
202 treatment. Clin Infect Dis, **2023**; 76: 573-581.
- 203 9. Vassilaki N, Gargalionis NG, Bletsas A, et al. Impact of Age and Sex on Antibody
204 Response Following the Second Dose of COVID-19 BNT162b2 mRNA Vaccine in Greek
205 Healthcare Workers. Microorganisms, **2021**; 9: 1725.

206 10. Shapiro JR, Sitaras I, Park H, et al. Association of Frailty, Age, and Biological Sex with
207 Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine-Induced
208 Immunity in Older Adults. Clin Infect Dis, **2022**; 75: 61-71.

209

210 **Figure 1. Antibody response to SARS-CoV-2 by NMV/r use among unmatched and**
211 **matched pairs.** Panel A: IC50 pre-infection and post-infection among unmatched participants
212 who took NMV/r (n = 21) and those who did not (n = 21). IC50 values are displayed using a log
213 scale of 10. Panel B: IC50 ratio of matched participants who took NMV/r versus those who did
214 not measured between pre-infection and post-infection serum samples (n = 21). The dashed
215 line represents an equivalent IC50 value (IC50 ratio = 1). IC50 ratio values are displayed using
216 a log scale of 2.

A**B**